HU Shuangshuang 1,2,3 , ZHANG Hui 1,2,3 , LIU Yuhang 1,2,3 , LIU Yonghui 1,2,3
  • 1. School of Pharmaceutical Business, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China;
  • 2. Research Center for Health Economics and Health Promotion, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China;
  • 3. Health Economics and General Health Research Center, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China;
ZHANG Hui, Email: zhanghui@gdpu.edu.cn
Export PDF Favorites Scan Get Citation

Objective From the perspective of the Chinese healthcare system, to evaluate the cost-effectiveness of six first-line treatment regimens for unresectable hepatocellular carcinoma (uHCC). Methods A partitioned survival model (PSM) was developed to compare the cost-effectiveness of atezolizumab plus bevacizumab, camrelizumab plus apatinib, sintilimab plus bevacizumab, donafenib, lenvatinib, and tislelizumab. The model cycle length was 3 weeks, and the time horizon was 10 years. The willingness-to-pay (WTP) threshold was set at three times the Chinese per capita gross domestic product (GDP) in 2025 (298 995 RMB/QALY). Primary outcome measures included total costs, quality-adjusted life years (QALY), incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB). Deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted to verify the robustness of the model. Results The base-case analysis showed that, compared with sorafenib, donafenib had an ICER of 164 020.14 RMB/QALY, the highest net monetary benefit, making it the most cost-effective option, followed by lenvatinib. The one-way sensitivity analysis revealed that the utility values for progression-free survival (PFS) and progressive disease (PD), as well as drug costs, had substantial impacts on the results. The probabilistic sensitivity analysis indicated that under budget constraints, tislelizumab, donafenib, and lenvatinib were more economical choices. Conclusion At the current WTP threshold in China, donafenib is the most cost-effective first-line treatment for uHCC. Although combination regimens offer better efficacy, they are associated with significant economic toxicity. It is recommended that treatment selection be individualized based on the patient's disease status and financial capacity, and that drug price adjustments be used to improve the accessibility of combination therapies.

Citation: HU Shuangshuang, ZHANG Hui, LIU Yuhang, LIU Yonghui. Pharmacoeconomic evaluation of first-line treatment regimens for unresectable hepatocellular carcinoma in China. Chinese Journal of Evidence-Based Medicine, 2026, 26(10): 1182-1188. doi: 10.7507/1672-2531.202604122 Copy

Copyright ? the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Fish oil-containing lipid emulsions for the prevention of parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis
  • Next Article

    Analysis of structure and academic influence of evidence-based medicine journals based on bibliometrics: a case study of Journal of Evidence-Based Medicine